Novartis Gleevec first-line approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approves Novartis' tyrosine kinase inhibitor Gleevec (imatinib) Dec. 20 for first-line treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia. Approval is based on 12-month data from the confirmatory International Randomized Study of Interferon vs. STI571 (IRIS) comparing Gleevec with the traditional CML regimen of interferon-alpha and cytosine arabinoside (Pharmaceutical Approvals Monthly, July 1, 2002, In Brief). Recently presented 18-month data showed an advantage in complete and major cytogenetic response and in progression-free survival. Data will be extrapolated to support a potentially imminent pediatric CML indicatio
You may also be interested in...
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market
Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.